Context: Acromegaly has been associated with calcium-phosphate and bone turnover alterations. Controlled studies of these interactions are sparse.
S
ome acromegaly patients exhibit hypercalcemia or hypercalciuria (1) (2) (3) . The etiology of hypercalcemia includes primary hyperparathyroidism (2, 4) or 1,25-dihydroxy-vitamin D [1, 25(OH) 2 D] excess (5, 6) . Studies in patients treated for acromegaly have reported that posttreatment mean parathyroid hormone (PTH) levels were unchanged (2) or higher compared with baseline (7, 8) . Similarly, mean 1,25(OH) 2 D levels decreased after treatment of acromegaly in some studies (2, 8, 9) and remained unchanged in others (10, 11) . A confounding factor may be coexisting hyperprolactinemia, as one report indicated patients with prolactinomas had higher 1,25(OH) 2 D levels than controls (12) . Prospective, controlled studies are needed to clarify these issues.
Patients with acromegaly have an increased radiographic incidence of vertebral fractures in absence of concordant bone mineral density changes (13) (14) (15) . Quantitative computed tomography seems more helpful in identifying structural bone changes in patients with acromegaly (16, 17) , but this is not currently used in clinical practice. Uncontrolled growth hormone (GH) excess, duration of acromegaly, coexistent diabetes mellitus, and hypogonadism have been associated with an increased risk of vertebral fractures (18) . Interestingly, the risk remains high for a few years after biochemical remission, suggesting a long-lasting effect of acromegaly on bone quality (19) . Bone formation and resorption are high in patients with active acromegaly (13) and decrease after medical treatment of acromegaly (7, 8, 10) . The mechanism by which GH excess induces bone resorption is unknown. Some studies suggest GH may alter the receptor activator of nuclear factor kB ligand (RANK-L)/osteoprotegerin (OPG) system (20, 21) ; however, these experiments were done in mouse cell cultures or plasma of GH-deficient patients.
We present here a prospective study of calcium homeostasis, bone turnover, and osteoclast markers in patients with acromegaly and a control group of nonfunctioning pituitary adenoma (NFPA) patients. Our aims are to determine: (1) the impact of active acromegaly on calcium balance and bone markers, (2) the etiology of calcium and bone metabolism perturbations, and (3) the effect of acromegaly treatment on calcium and bone metabolism. To our knowledge, this is the first controlled, prospective study that comprehensively evaluates the relationship between acromegaly and calcium/bone metabolism.
Materials and Methods

Patients and study design
Between January 2012 and September 2013, we studied 44 consecutive patients who presented to the pituitary endocrine clinic with uncontrolled (active) acromegaly [22 patients, acromegaly referred for surgical or medical therapy (ACM) group] or nonfunctioning macroadenomas (22 patients, control group) who agreed to participate in the study. Eligibility criteria included age $18 and ability to provide written informed consent. Patients with chronic renal disease stage III or worse [estimated glomerular filtration rate (GFR) ,60 mL/min/1.73 m 2 by Modification of Diet in Renal Disease equation] were excluded. The research protocol was reviewed and approved by the Emory University institutional review board and registered with ClinicalTrials.gov (identifier NCT01568359).
The diagnosis of acromegaly was made using standard diagnostic criteria, per Endocrine Society guidelines (22) . We defined active acromegaly as elevation of insulin growth factor-1 (IGF-1) level above age-and sex-adjusted normal range.
Intervention
Clinical management of the pituitary condition was done according to the current standards of care (22, 23) . Patients with ACM underwent surgical or medical therapy, whereas patients in the control group underwent transsphenoidal surgery. Patients who underwent a surgical intervention obtained laboratory studies at baseline and 3 months postoperatively. Patients who received medical therapy for ACM had laboratory studies at baseline and 3 to 6 months after initiation of treatment.
Measurements
As part of the study protocol, the following parameters were collected after fasting 10 to 12 hours: serum calcium, albumin (Alb), creatinine, phosphorus, PTH, 25-hydroxy-vitamin D [25(OH)D], 1,25(OH) 2 D, C-terminal telopeptide of type 1 collagen (CTX), and procollagen type 1 N-terminal propeptide (P1NP). Subjects also provided 24-hour urine samples for measurement of urinary calcium and creatinine. Plasma of a subgroup of 20 patients (14 ACM and 6 NFPA) was tested for cytokines RANK-L and OPG.
We calculated corrected serum calcium for the Alb level, based on the formula calcium + 0.8 (4-Alb).
As part of the standard of care, the following parameters were measured: IGF-1, random GH, cortisol, thyroid-stimulating hormone, free thyroxine, and testosterone in men. Patients with clinical or biochemical suspicion of corticoadrenal insufficiency underwent adrenocorticotropic hormone stimulation test (250 mg); cutoff used for diagnosis was peak serum cortisol level ,20 mg/dL.
We did not perform bone densitometry testing as part of the study protocol. Patients completed a questionnaire that included history of fractures, osteopenia or osteoporosis, and current vitamin D supplementation.
Laboratory assays
Intact PTH was measured using a chemiluminescence-based automated instrument, with a normative range of 14 to 72 pg/mL (BeckmanCoulter, Brea, CA). Serum 25(OH)D was measured using a chemiluminescence-based automated instrument (IDS-iSYS; Immunodiagnostic Systems, Scottsdale, AZ), and quality control was assured by participation in the vitamin D external quality assessment scheme (www.deqas. prg). Serum 1,25(OH) 2 D was measured in duplicate using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Immunodiagnostic Systems). CTX and P1NP were measured using a chemiluminescence-based automated instrument (IDS-iSYS; Immunodiagnostic Systems). Normative ranges were as follows: P1NP, 27.7 to 127.6 ng/mL; CTX males, 0.115 to 0.748 ng/mL; CTX premenopausal women, 0.112 to 0.738 ng/mL; and CTX postmenopausal women, 0.142 to 1.351 ng/mL. Serum RANK-L was run in double antibody using an ELISA kit (BioVendor, Ashville, NC). Serum OPG was run in double antibody using an ELISA kit (RayBiotech, Norcross, GA). For RANK-L, a study of 39 men and women ages 25 to 65 yielded a mean value of 339.34 (standard error of the mean of 42.3 pmol/L). For OPG, the mean 6 standard devation was 69 6 19 pg/mL (derived from a study of 27 nonpregnant women) (24) .
IGF-1, GH, and prolactin (PRL) were determined by chemiluminescence immunoassay.
Statistical methods
Power calculation analysis was based on a previous study that indicated a number of six patients with acromegaly yielded a 90% power to detect a difference of 1,25(OH) 2 D means of 15.6 pg/mL with a significance level of 0.05 before and after treatment (2) . Sample sizes were estimated using GraphPad StatMate. For the control group, based on the same study by Takamoto et al., a sample size of 10 in each group would yield a 90% power to detect a difference between 1,25(OH) 2 D means of 20.60 pg/mL with a significance level of 0.05 (two-tailed) (2) . To account for hyperprolactinemia and patient dropout, we enrolled 22 patients with acromegaly. To attain a 1:1 ratio with the ACM group, 22 subjects were enrolled in the control group.
We performed a x 2 test (Tukey honest significant difference or Wilcoxon/Kruskal-Wallis) to detect differences between categorical variables and analysis of variance for continuous variables. We used Spearman correlations to evaluate the relationship between continuous variables. We used linear and logistic regression to determine the influence of different factors of bone resorption markers. Stepwise regression analysis was performed to evaluate potential determinant factors of CTX levels. Variables are presented as mean 6 standard deviation if normally distributed and median interquartile range if nonnormally distributed. Analyses were performed using the JMP 10 Pro Software (SAS Institute, Cary, NC). Values of P , 0.05 were considered statistically significant.
Results
Patients
The ACM group included 22 patients (11 women, age 30 to 69 years, and 11 men, age 22 to 71 years); the control group (NFPA) included 22 patients (8 women, age 30 to 62 years, and 14 men, age 38 to 67 years). In the ACM group, 10 patients were naïve to surgical or medical treatment, whereas 12 patients underwent prior treatment: 9 with pituitary surgery and 3 with pharmacologic therapy (cabergoline in 1 patient, lanreotide depot in 1 patient, and combination of cabergoline with lanreotide depot in 1 patient). In the control group, 18 patients were naïve to surgical or medical treatment, and 4 patients had prior treatment: 2 with pituitary surgery and 2 with medical treatment (cabergoline and bromocriptine, respectively).
In the ACM group, measurements done at study entry indicated high IGF-1 in 19 of 22 patients. The other three patients were in biochemical control on medical treatment with lanreotide depot and/or cabergoline. All patients in the control group had normal IGF-1 levels. Hyperprolactinemia was detected in six patients in the ACM group and three patients in the control group.
Patients in both groups denied having history of fractures, except one female patient in the ACM group who had three stress fractures as a teenager during sport activities. Two women in the ACM group reported history of abnormal bone densitometry testing: osteopenia in a 55-year-old woman with coexistent primary hyperparathyroidism and osteoporosis in a 63-year-old postmenopausal woman. No patients in the control group reported a diagnosis of osteopenia or osteoporosis. Seven patients in the ACM group and five patients in the control group did not have bone densitometry. Four patients in the ACM group and three control patients were taking vitamin D replacement, which was continued during the study. One patient in the ACM group and two patients in the control group were taking daily calcium supplements. Six patients in the ACM group and six in the control group were taking a multivitamin daily. Hypercalciuria (.300 mg/d) was found in 4 of 18 patients who submitted the urine collection (22%) in the ACM group and 1 of 18 patients (5.5%) in the control group. Hyperphosphatemia (.4.7 mg/dL) was detected in five ACM patients and none in the control group. Hyperphosphatemia resolved in all except one patient whose IGF-1 level was still elevated after treatment. Vitamin D deficiency (,30 ng/dL) was present in 8 patients in the ACM and 14 patients in the control group. Elevated PTH levels (.72 pg/mL) were identified in one patient in the ACM group with primary hyperparathyroidism and four patients in the control group who also had 25(OH)D deficiency.
Calcium and bone metabolism parameters before treatment
Analyses to ascertain differences between acromegaly and control group (Table 1) as well as changes after treatment (Table 2) were based on 17 ACM and 22 control patients. Five patients in the ACM group were excluded from analyses for the following reasons: normal baseline IGF-1 (three patients), baseline primary hyperparathyroidism (one patient), and higher IGF-1 at end of the study than baseline (one patient).
Baseline parameters in ACM and control groups are illustrated in Table 1 . ACM patients were younger, but sex, weight, waist circumference, prevalence of diabetes mellitus, hypogonadism, corticoadrenal insufficiency, and hypothyroidism were comparable with controls. Also, estimated GFR and mean PRL levels were similar in both groups. At baseline, three patients had corticoadrenal insufficiency (one in the ACM group and two in the control group) and were receiving physiologic doses of hydrocortisone (10 mg/m 2 /d). Five patients had hypothyroidism (two in the ACM group and three in the control group), of whom three had replacement with levothyroxine and had normal free T4 levels. Hypogonadism was found in 8 patients in the ACM group (47%) and 12 in the control group (54.5%); of them, 1 patient in each group was receiving gonadal steroid replacement, and both had normal testosterone levels. The proportion of patients undergoing cortisol, thyroid, and gonadal steroid hormone replacement was similar between groups (individual P values . 0.05).
Mean serum phosphorus was higher and PTH was lower in ACM vs control. Mean serum and urine calcium, 25(OH)D, and 1,25(OH) 2 D levels were similar between groups. In the ACM group, IGF-1 level positively correlated with serum calcium level (r 2 = 0.32, P = 0.01) (Fig. 1 ) and serum phosphorus (r 2 = 0.11, P = 0.009) (Fig. 2) . On the other hand, IGF-1 inversely correlated with serum PTH level (r 2 = 0.18, P , 0.05) (Fig. 3) . These correlations were not found in the control group. There was no correlation between IGF-1 and 1,25(OH) 2 D levels in both groups.
Markers of bone resorption and formation were higher in ACM vs control. In the ACM group, CTX significantly correlated with P1NP (r 2 = 0.82, P , 0.001). A correlation was also observed for the control group (r 2 = 0.47, P ,
0.001).
Stepwise regression analysis showed that baseline CTX was determined by age and disease group, whereas sex and hypogonadism were not significant. Cytokines OPG and RANK-L were weakly correlated (r 2 = 0.17, P = 0.06) (Fig. 4) . The acromegaly group did not have higher levels of OPG and RANK-L compared with control. Furthermore, there was no correlation between OPG, RANK-L, or RANK-L/OPG ratio with IGF-1 levels.
Effect of treatment on calcium metabolism
In the active ACM group, the following treatments were performed during the study interval: transsphenoidal surgery (eight patients), medical therapy (six patients), surgery followed by medical therapy (one patient), medical and radiation treatment (one patient), or no intervention (one patient). Medical therapy during the study interval consisted of the following: somatostatin analogs in eight patients (six lanreotide depot and two octreotide longacting release), pegvisomant (1), and cabergoline (1). At study end, eight patients had normal IGF-1 (five postsurgery, two on lanreotide depot, and one on sandostatin long-acting release), and nine had improved IGF-1.
The changes in calcium and bone parameters in the ACM group after treatment of acromegaly are illustrated in Table 2 .
In the active ACM group, serum calcium, fractional excretion of calcium, and phosphorus significantly decreased, whereas PTH increased. Mean vitamin 25(OH)D and 1,25-(OH) 2 D levels did not significantly change. Both GH and IGF-1 levels decreased, whereas there was no significant change in mean PRL level. Both patients with PTH-independent hypercalcemia had a decrease in CTX levels by more than 50% and no decrease in P1NP. In the control group, there were no significant changes of IGF-1, GH, or PRL levels after surgical treatment. Also, serum and urinary calcium, phosphorus, PTH, and 1,25-(OH) 2 D were unchanged. There was an increase in mean 25-OH-D (35.3 6 18.0 ng/mL) (P , 0.05).
Effect of treatment on bone metabolism
At study end, four patients had corticoadrenal insufficiency (two in the ACM group and two in the control group) and were receiving physiologic doses of hydrocortisone. Six patients had hypothyroidism (two in the ACM group and four in the control group) and were treated with levothyroxine, which resulted in normal free T4 levels. Hypogonadism was found in seven patients in the ACM group (41.2%) and in nine controls (40.9%); of them, one patient in each group was receiving gonadal steroid replacement, with normal testosterone levels. At study end, the proportion of patients undergoing cortisol, thyroid, and gonadal steroid hormone replacement was similar between groups (individual P values . 0.05).
In the active ACM group, CTX decreased after treatment, whereas P1NP did not change significantly. Levels of RANK-L and OPG remained unchanged; some patients experienced decreased RANK-L and increased OPG, whereas others experienced the opposite. Also, there was no significant change of the RANK-L/OPG ratio after treatment of acromegaly.
In the control group, CTX was unaltered, whereas P1NP increased from baseline. There were no significant changes of the RANK-L/OPG ratio.
At study end, stepwise regression analysis indicated that age was the only significant parameter predictive of CTX, whereas disease group (ACM vs control), sex, and hypogonadism were not significant.
Discussion
We have shown that patients with acromegaly exhibit PTH-independent calcium-phosphate alterations, even in absence of overt hypercalcemia. These correlate with disease activity and are reversible after treatment. Furthermore, patients with uncontrolled acromegaly have evidence of increased bone formation and resorption, processes that are strongly coupled. At 3 to 6 months after treatment, only bone resorption decreased; this implicates bone resorption as contributory to calcium perturbations in active acromegaly. The mechanisms of increased bone resorption remain unclear as the RANK-L/OPG system does not change after treatment of acromegaly.
Calcium changes in acromegaly
Hypercalcemia has been reported in 5% to 10% and hypercalciuria in 47% to 68% cases of acromegaly (1, 2). Although the etiology has not been consistently documented in prospective or cross-sectional studies, case reports demonstrated either concomitant primary hyperparathyroidism (3) or 1,25(OH) 2 D excess, the latter reversible after biochemical remission of acromegaly (5, 6). Our study found a prevalence of hypercalcemia of 13%, with one case (4.5%) due to primary hyperparathyroidism that persisted after treatment of acromegaly. The other two cases (8.5%) exhibited mild hypercalcemia (,11 mg/dL) that could not be attributed to PTH or 1,25(OH) 2 D excess and resolved after treatment of acromegaly. Interestingly, along with normalization of calcium levels, PTH increased in both cases, whereas phosphorus and CTX decreased. Furthermore, our study identified hypercalciuria in 22% patients, which resolved in patients who had normalization of IGF-1. Even in normocalcemic acromegaly patients, we identified changes of calciumphosphate balance after treatment of acromegaly: a decrease in mean serum and urine calcium, along with a decrease in phosphorus levels. This is consistent with previous studies that indicated a decrease in serum calcium level at 3 to 4 weeks after pituitary surgery (8) and 3 to 4 months after treatment with somatostatin analogs (7, 10) . The role of 1,25(OH) 2 D in calcium perturbations in acromegaly has been attributed to the activation of renal 1-a-hydroxylase by GH (25) or PRL (26) . Other possible mechanisms include higher 25(OH)D production due to larger skin surface in acromegaly. Treatment of acromegaly with surgery (2) or a GH receptor antagonist (8) resulted in a reduction of mean 1,25(OH) 2 D levels, whereas GH supplementation in GH-deficient adults had the opposite effect (27) . On the other hand, a reduction of mean 1,25(OH) 2 D levels has not been found in longitudinal studies where patients were treated with somatostatin analogs (10, 11 (5) . The patient population enrolled in prior studies was heterogeneous with regards to the duration and biochemical severity of acromegaly, while assays for IGF-1 and 1,25(OH) 2 D have also evolved. Our study is, to our knowledge, the first to control for the possible effect of hyperprolactinemia and to exclude patients with a reduced GFR. In addition, there were no differences in mean 25(OH)D levels between the two groups we studied.
The role of PTH in calcium perturbations in acromegaly has been unclear. Parathyroid hyperplasia was demonstrated in rats who received GH injections (28) . However, studies in patients with acromegaly found normal PTH levels, which either did not change (2) or increased after treatment of acromegaly (7, 8) . Furthermore, mean PTH levels were higher after 12 to 24 months of treatment with somatostatin analogs despite decreasing serum calcium to pretreatment values (7, 10) . This has been attributed to decreased intestinal calcium absorption by somatostatin analogs, with subsequent secondary hyperparathyroidism. In our study, patients with active acromegaly had lower mean PTH levels compared with controls and increased PTH levels after treatment, regardless of treatment modality. Also, PTH inversely correlated with IGF-1 levels in patients with active acromegaly. Hence, PTH changes appear reactive to calcium modifications. Although further studies are needed to determine whether somatostatin analogs induce malabsorption of calcium, this is unlikely to be a major factor. Another important observation is that PTH does not parallel 1,25(OH) 2 D levels, suggesting a different mechanism of alteration of calciotropic hormones in acromegaly.
Bone metabolism in acromegaly
Patients with acromegaly have increased risk of vertebral fractures that is not reflected by bone mineral density measured by dual-energy X-ray absorptiometry (13-15), and specific therapy is lacking. One notable exception is that patients with hypogonadism benefit from antiresorptive treatment. Previously, biochemical markers of bone formation and bone resorption are higher in patients with acromegaly (13) and respond to medical treatment of acromegaly (7, 8, 10) . Despite reversible changes of bone turnover markers, the risk of vertebral fractures persists in controlled acromegaly, indicating durable detrimental effects on bone structure. Our study confirms higher bone resorption and formation markers in active acromegaly compared with control, as well as strong coupling of bone formation and resorption. Nevertheless, after 3 to 6 months of treatment, only bone resorption significantly decreased. Corroboration of our data with previous studies suggests a temporary uncoupling of bone resorption and formation and supports the hypothesis of increased calcium demand in acromegaly.
Mechanisms of bone disease in acromegaly are poorly understood. Although it is widely accepted that systemic and locally produced IGF-1 stimulates the osteoblasts, the pathogenesis of increased bone resorption in acromegaly is unknown. Osteoclasts express IGF-1 and IGF-1 receptors. One hypothesis is that GH/IGF-1 stimulates the production of cytokines implicated in osteoclast regulation, such as interleukin-6 (29), and tumor necrosis-factor-a (30) . In addition, the interaction between osteoclasts and adipocytes with modification of the canonical wingless (Wnt) signaling pathway may play a role (31) . Studies in animals and GH-deficient patients suggested the RANK-L/OPG system might mediate the IGF-1 effect on osteoclast (20, 21) . RANK-L stimulates osteoclast differentiation and maturation and inhibits osteoclast apoptosis. OPG, a RANK-L decoy receptor, blocks the effects of RANK-L. Therefore, a decrease in the RANK-L/OPG ratio would be expected after treatment of acromegaly. Our study, however, did not confirm this hypothesis. A possible explanation is that RANK-L and OPG are systemic cytokines produced by skeletal and nonskeletal tissues, and hence plasma levels may not reflect local cytokine production.
Limitations
Our study has several limitations, including relatively small size and treatment of acromegaly by either surgery or medical treatment. In addition, the ACM group was younger than the control group, which could have influenced bone marker results. However, the posttreatment measurements of bone markers and regression analyses demonstrated bone resorption alterations were influenced by the high IGF-1 levels. The follow-up period was 3 months in patients who underwent surgery and 6 months in patients treated medically. Therefore, longer studies are needed to elucidate the timing of bone formation resolution after treatment of acromegaly.
In summary, the mechanisms of calcium-phosphate perturbations and bone resorption in acromegaly are complex and involve several sites, including the kidneys, the intestinal tract, and bone. Excess PTH is rarely involved in cases of hypercalcemia due to concomitant primary hyperparathyroidism, which persists after treatment of acromegaly. Excess of 1,25(OH) 2 D can also be encountered in rare cases of hypercalcemia that resolve after biochemical control of acromegaly. Increased bone resorption in acromegaly may be an important contributor to calcium balance. Future studies are needed to elucidate the effect of excess GH on osteoclasts.
